MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes

H. Pourhassan; T. Defor; B. Trottier; M. Dolan; C. Brunstein; N. Bejanyan; C. Ustun; E. D. Warlick

doi:10.1038/bmt.2016.303

MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes

H. Pourhassan, T. Defor, B. Trottier, M. Dolan, C. Brunstein, N. Bejanyan, C. Ustun, E. D. Warlick

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous group of hematological malignancies with considerably variable prognoses and curable only with hematopoietic cell transplantation (HCT). Few studies comparing MDS HCT outcomes between sibling and umbilical cord blood (UCB) donors exist. Using the University of Minnesota Blood and Marrow Transplant (BMT) database, we retrospectively analyzed HCT outcomes among 89 MDS patients undergoing either sibling or double UCB HCT in 2000-2013. We observed similar survival, relapse and non-relapse mortality between sibling and UCB donor sources. Relapse was increased in those with monosomal karyotype (P=0.04) and with reduced intensity conditioning (P<0.01). In summary, our data highlight similar MDS HCT outcomes regardless of donor source and support the use of UCB as an alternative donor when a sibling is unavailable.

Original language	English (US)
Pages (from-to)	532-538
Number of pages	7
Journal	Bone marrow transplantation
Volume	52
Issue number	4
DOIs	https://doi.org/10.1038/bmt.2016.303
State	Published - Apr 1 2017

Bibliographical note

Publisher Copyright:
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.

Access

10.1038/bmt.2016.303

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382091

OpenUrl availability

Full text

Cite this

@article{9daa1fe02e4e4cdab4c8f7484ce2cd99,

title = "MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes",

abstract = "Myelodysplastic syndrome (MDS) is a heterogeneous group of hematological malignancies with considerably variable prognoses and curable only with hematopoietic cell transplantation (HCT). Few studies comparing MDS HCT outcomes between sibling and umbilical cord blood (UCB) donors exist. Using the University of Minnesota Blood and Marrow Transplant (BMT) database, we retrospectively analyzed HCT outcomes among 89 MDS patients undergoing either sibling or double UCB HCT in 2000-2013. We observed similar survival, relapse and non-relapse mortality between sibling and UCB donor sources. Relapse was increased in those with monosomal karyotype (P=0.04) and with reduced intensity conditioning (P<0.01). In summary, our data highlight similar MDS HCT outcomes regardless of donor source and support the use of UCB as an alternative donor when a sibling is unavailable.",

author = "H. Pourhassan and T. Defor and B. Trottier and M. Dolan and C. Brunstein and N. Bejanyan and C. Ustun and Warlick, {E. D.}",

year = "2017",

month = apr,

day = "1",

doi = "10.1038/bmt.2016.303",

language = "English (US)",

volume = "52",

pages = "532--538",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes

AU - Pourhassan, H.

AU - Defor, T.

AU - Trottier, B.

AU - Dolan, M.

AU - Brunstein, C.

AU - Bejanyan, N.

AU - Ustun, C.

AU - Warlick, E. D.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Myelodysplastic syndrome (MDS) is a heterogeneous group of hematological malignancies with considerably variable prognoses and curable only with hematopoietic cell transplantation (HCT). Few studies comparing MDS HCT outcomes between sibling and umbilical cord blood (UCB) donors exist. Using the University of Minnesota Blood and Marrow Transplant (BMT) database, we retrospectively analyzed HCT outcomes among 89 MDS patients undergoing either sibling or double UCB HCT in 2000-2013. We observed similar survival, relapse and non-relapse mortality between sibling and UCB donor sources. Relapse was increased in those with monosomal karyotype (P=0.04) and with reduced intensity conditioning (P<0.01). In summary, our data highlight similar MDS HCT outcomes regardless of donor source and support the use of UCB as an alternative donor when a sibling is unavailable.

AB - Myelodysplastic syndrome (MDS) is a heterogeneous group of hematological malignancies with considerably variable prognoses and curable only with hematopoietic cell transplantation (HCT). Few studies comparing MDS HCT outcomes between sibling and umbilical cord blood (UCB) donors exist. Using the University of Minnesota Blood and Marrow Transplant (BMT) database, we retrospectively analyzed HCT outcomes among 89 MDS patients undergoing either sibling or double UCB HCT in 2000-2013. We observed similar survival, relapse and non-relapse mortality between sibling and UCB donor sources. Relapse was increased in those with monosomal karyotype (P=0.04) and with reduced intensity conditioning (P<0.01). In summary, our data highlight similar MDS HCT outcomes regardless of donor source and support the use of UCB as an alternative donor when a sibling is unavailable.

UR - http://www.scopus.com/inward/record.url?scp=85016949409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016949409&partnerID=8YFLogxK

U2 - 10.1038/bmt.2016.303

DO - 10.1038/bmt.2016.303

M3 - Article

C2 - 27941767

AN - SCOPUS:85016949409

SN - 0268-3369

VL - 52

SP - 532

EP - 538

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 4

ER -

MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this